Guanfacine Dosing
For hypertension in adults, start guanfacine immediate-release at 1 mg once daily at bedtime, and if needed after 3-4 weeks, increase to 2 mg daily; for ADHD in adults, start guanfacine extended-release at 2 mg daily and titrate to a maintenance dose of 4-6 mg daily over 5 weeks, with no dosage adjustment required for renal impairment. 1, 2
Immediate-Release Guanfacine for Hypertension
Initial Dosing
- Start at 1 mg once daily at bedtime to minimize somnolence 1
- Can be used alone or combined with other antihypertensives 1
Titration Schedule
- Assess response after 3-4 weeks at 1 mg 1
- If inadequate response, increase to 2 mg daily 1
- Most therapeutic effect occurs at 1 mg; doses above 3 mg/day significantly increase adverse reactions 1
- Higher doses (up to 25 mg) have been used historically, but 2-4 mg daily is optimal based on clinical experience, with better normalization rates and fewer side effects at lower doses 3, 4
Dosing Frequency
- Once-daily or twice-daily dosing is recommended rather than three times daily, given the 17-hour elimination half-life 1, 3
- Bedtime dosing minimizes daytime somnolence 1
Extended-Release Guanfacine for ADHD in Adults
Initial Dosing and Titration
- Start at 2 mg once daily 2
- Titrate over 5 weeks to maintenance dose of 4-6 mg daily 2
- Follow with 5-week maintenance period at 4-6 mg daily 2
Discontinuation
- Taper over 2 weeks down to 2 mg before stopping 2
- Abrupt discontinuation can be done without significant rebound hypertension, though tapering is preferred 5
- Rebound phenomena are infrequent and delayed (2-4 days) compared to clonidine 1
Efficacy Data
The maximum approved dose of 6 mg daily in Japan showed significant improvement in ADHD-RS-IV total scores (effect size 0.52) with 48.1% of patients achieving much/very much improved status on CGI-I 2. Long-term administration (50 weeks) maintained efficacy without major safety concerns 6.
Renal Impairment Adjustments
No dosage adjustment is required for renal impairment, though starting at the lower end of the dosing range is prudent 1, 7. This recommendation is based on:
- Guanfacine has dual renal and nonrenal clearance (approximately 50% excreted unchanged in urine, 50% as metabolites) 1
- Plasma levels increase only slightly in renal insufficiency despite reduced clearance 1, 7
- The drug is poorly dialyzed, so usual doses can be given to dialysis patients 1
- Elderly patients show age-related decreases in renal clearance but compensatory increases in metabolic clearance 7
Key Safety Considerations
Common Adverse Effects
- Somnolence (most common, reported in 63.5% in one study) 8
- Thirst, decreased blood pressure, postural dizziness 2
- Bradycardia, constipation, nasopharyngitis 2, 6
- Most adverse events are mild to moderate in severity 2, 6
Monitoring Parameters
- Blood pressure and heart rate (expect 5 bpm decrease and modest BP reduction) 1
- Discontinuation rates due to adverse events: 19.8% for extended-release in ADHD trials 2
Clinical Pitfalls
- Avoid doses above 3 mg/day for hypertension unless absolutely necessary, as adverse reactions increase significantly 1
- The 2017 ACC/AHA hypertension guidelines recommend considering behavioral therapies for ADHD as an alternative strategy when guanfacine is being used for ADHD and causes blood pressure concerns 9
- Peak plasma concentrations occur 1-4 hours post-dose (average 2.6 hours), with steady state achieved within 4 days 1